The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, hypercholesterolemia.

##STR00001##

The present invention discloses an amino lipid compound, a preparation method and use of the same. The present invention also provides lipid particles comprising the amino lipid compound, and use thereof for delivering bioactive agents into cells. The present invention also provides a use of lipid particles comprising the amino lipid as a medicament.

The present invention discloses an amino lipid compound, a preparation method and use of the same. The present invention also provides lipid particles comprising the amino lipid compound, and use thereof for delivering bioactive agents into cells. The present invention also provides a use of lipid particles comprising the amino lipid as a medicament.

Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.

The present invention provides novel compounds having a P2X.sub.3 and/or P2X.sub.2/3 receptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): ##STR00001##
wherein
R.sup.h and R.sup.i are taken together to form a bond; R.sup.a and R.sup.b and/or R.sup.d and R.sup.e are taken together to form oxo or the like; R.sup.c is hydrogen, substituted or unsubstituted alkyl or the like;
R.sup.f is —(CR.sup.4aR.sup.4b).sub.n—R.sup.2; R.sup.4a and R.sup.4b are hydrogen, substituted or unsubstituted alkyl or the like; R.sup.2 is substituted or unsubstjtuted cycloalkyl or the like; n is an integer of 1 to 4; —R.sup.g is —X—R.sup.3; —X— is —O—, —S— or the like; R.sup.3 is substituted or unsubstituted cycloalkyl or the like,
or its pharmaceutically acceptable salt or a solvate thereof.

The present invention provides novel compounds having a P2X.sub.3 and/or P2X.sub.2/3 receptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): ##STR00001##
wherein
R.sup.h and R.sup.i are taken together to form a bond; R.sup.a and R.sup.b and/or R.sup.d and R.sup.e are taken together to form oxo or the like; R.sup.c is hydrogen, substituted or unsubstituted alkyl or the like;
R.sup.f is —(CR.sup.4aR.sup.4b).sub.n—R.sup.2; R.sup.4a and R.sup.4b are hydrogen, substituted or unsubstituted alkyl or the like; R.sup.2 is substituted or unsubstjtuted cycloalkyl or the like; n is an integer of 1 to 4; —R.sup.g is —X—R.sup.3; —X— is —O—, —S— or the like; R.sup.3 is substituted or unsubstituted cycloalkyl or the like,
or its pharmaceutically acceptable salt or a solvate thereof.

Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.

Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.

Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.

Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.